Navigation Links
Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
Date:3/13/2009

t assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Lexicon Appoints Judith Swain, M.D. to Board of Directors
4. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
5. Lexicon Pharmaceuticals to Present at Bio InvestorForum
6. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
7. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
8. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
9. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
10. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
11. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Global Chelating ... About Chelating Agent A chelating ... covalent bonds with metal ions, thereby forming a ... some metal-ions have on chemical processes, formulations, and ...
(Date:8/27/2014)... Aug. 27, 2014  Lisa Kulik saw fireworks for ... 4 holiday, thanks to a groundbreaking retinal implant co-invented ... renowned clinician-researcher at the University of Southern California (USC) ... Peoria, Ariz. resident who has retinitis ... of sight. On June 2, she became the first ...
(Date:8/27/2014)... “We are honored to be named to ... CEO of Radiant Sage. “We are offering truly ground-breaking ... corelab market to a different level. We are ... efficiently and effectively manage the massive amounts of medical ... and read by trained physicians. Being recognized by technology ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com ... The Graphene Opportunity - A Rational View ... Graphene The New Nanotech? A similar amount ... of applications ranging from microelectronics to water treatment, ... announced the availability of the Graphene Opportunity Report, ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... , Amsterdam Molecular Therapeutics (Euronext: AMT), ... today that it has filed,a request for re-examination of ... European Medicines Agency.,Glybera is a gene therapy for the ... re-examination of,the dossier will be completed by the end ...
... a combination of sophisticated computer modeling and advanced ... team led by the University at Buffalo (UB) ... Technology (NIST), the Molecular Foundry at Lawrence Berkeley ... relatively simple processing flaws can seriously degrade the ...
... 7, 2011 For the first time since stem ... isolated a human blood stem cell in its purest ... regenerating the entire blood system. This breakthrough opens the ... to treat cancer and other debilitating diseases more effectively. ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination 2Graphene: What can go wrong? new studies point to wrinkles, process contaminants 2"Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use 2"Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use 3
(Date:8/27/2014)... Warwick research finds , Gamblers show the same ... research has shown. , Researchers, led by Dr Elliot ... conducted tests that found that both human gamblers and ... than low-value rewards. , Published in Biology Letters ... the important role that memories of previous biggest wins ...
(Date:8/26/2014)... over a colony of harmful bacteria, biofilms make ... protected in a biofilm pose a significant health ... to treatment, and biofilm-protected bacteria account for some ... and are 50 to 1,000 times more resistant ... essence, we may have stumbled onto a magic ...
(Date:8/26/2014)... In recent years, increasing pressure from policymakers, consumers, ... targets that go beyond reducing the pollutants they ... and lakes. Today companies must also assess environmental ... the mining of primary materials to the use ... has given rise to the discipline known as ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Yale journal explores advances in sustainable manufacturing 2
... Candida albicans inconspicuously lives in our bodies until it ... go on the offensive. The fungus, known for causing yeast ... as candidemia in immunocompromised patients. An in vivo study, published ... can distinguish between a healthy and an unhealthy host and ...
... The northern spotted owl, a threatened species in ... run from active management of the forest lands that ... stand-replacing fire, researchers conclude in a recent study. ... or other fuel reduction activities in areas with high ...
... Antarctic Program Blue Ribbon Panel, commissioned by the ... (OSTP) and the National Science Foundation (NSF) released ... through Increased Logistical Effectiveness. The report is a ... containing numerous specific recommendations for the U.S. logistics ...
Cached Biology News:How a common fungus knows when to attack 2Active forest management to reduce fire could help protect northern spotted owl 2Blue Ribbon Panel unveils findings on logistical improvements to support Antarctic science 2
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
Silica bead method is an economic method of DNA extraction from agarose...
5 minutes from gel band to purified DNA...
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-MSC 2 x 109 cells...
Biology Products: